User profiles forSanjay Ramakrishnan
 |
Sanjay Ramakrishnan
Clinical Research Fellow, University of Oxford; PhD student, Edith Cowan University
Verified email at ndm.ox.ac.uk
Cited by 393 |
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
SRamakrishnan,DV Nicolau Jr, B Langford… - The Lancet Respiratory …, 2021 - Elsevier
Background Multiple early reports of patients admitted to hospital with COVID-19 showed
that patients with chronic respiratory disease were significantly under-represented in these …
that patients with chronic respiratory disease were significantly under-represented in these …
[HTML][HTML]Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label …
Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
[HTML][HTML]Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
BACKGROUND Inhaled budesonide has shown efficacy for treating COVID-19 in the
community but has not yet been tested in effectiveness trials. METHODS We performed a …
community but has not yet been tested in effectiveness trials. METHODS We performed a …
[HTML][HTML]Standardisation of clinical assessment, management and follow-up of acute hospitalised exacerbation of COPD: a Europe-wide consensus
SRamakrishnan, W Janssens,PR Burgel… - … Journal of Chronic …, 2021 - ncbi.nlm.nih.gov
Background Despite hospitalization for exacerbation being a high-risk event for morbidity and
mortality, there is little consensus globally regarding the assessment and management of …
mortality, there is little consensus globally regarding the assessment and management of …
Blood eosinophil depletion with mepolizumab, Benralizumab, and prednisolone in eosinophilic asthma
AM Moran,SRamakrishnan, CA Borg… - American Journal of …, 2020 - atsjournals.org
Methods This was a substudy of the Oxford Airways Study (Integrated Research Application
System Project number: 234581; Oxfordshire Research Ethics Committee B Reference: 18/…
System Project number: 234581; Oxfordshire Research Ethics Committee B Reference: 18/…
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
S Couillard, A Laugerud, M Jabeen,SRamakrishnan… - Thorax, 2022 - thorax.bmj.com
Reduction of the risk of asthma attacks is a major goal of current asthma management. We
propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count …
propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count …
结合固定剂量ta agonist and steroid inhaler as required for adults or children with mild asthma
…, S Turner,SRamakrishnan… - Cochrane Database …, 2021 - cochranelibrary.com
Background Asthma affects 350 million people worldwide including 45% to 70% with mild
disease. Treatment is mainly with inhalers containing beta₂‐agonists, typically taken as …
disease. Treatment is mainly with inhalers containing beta₂‐agonists, typically taken as …
The use of benralizumab in the treatment of near-fatal asthma: a new approach
SRamakrishnan, JR Camp, B Vijayakumar… - American journal of …, 2020 - atsjournals.org
Background Mr. C is a 52-year-old never smoker who received a diagnosis of asthma at age
36. Of note, his medical history included CSR, with complete visual loss, after a trial of oral …
36. Of note, his medical history included CSR, with complete visual loss, after a trial of oral …
Antibiotics for asthma attacks: masking uncertainty
SRamakrishnan,S Couillard- European Respiratory Journal, 2021 - Eur Respiratory Soc
Despite current guidelines advising against, GPs commonly prescribe antibiotics with steroids
for asthma attacks. The uncertainty caused by a symptom-based management paradigm …
for asthma attacks. The uncertainty caused by a symptom-based management paradigm …
Inhaled budesonide for early treatment of COVID-19–Authors' reply
SRamakrishnan,M Bafadhel- The Lancet Respiratory Medicine, 2021 - thelancet.com
We share the enthusiasm of Rafael San-Juan and colleagues, Markus Zeitlinger and Marco
Idzko, and Jae Chol Choi and Won-Young Kim in the search for an effective treatment in …
Idzko, and Jae Chol Choi and Won-Young Kim in the search for an effective treatment in …